United Homes Group stock plunges after Nikki Haley, directors resign
Director Dunlop A. Sinclair of Apellis Pharmaceuticals Inc (NASDAQ:APLS), a biotech company with a market capitalization of $3.17 billion, recently sold 31,092 shares of common stock on October 10, 2025, for a total of $737,536. The shares were sold at weighted average prices ranging from $23.47 to $23.93, below the current trading price of $25.24. According to InvestingPro analysis, APLS shows signs of being slightly undervalued, with the stock posting an impressive 38.88% return over the past six months.
The transaction was executed indirectly through Epidarex, with Sinclair being a general partner and potentially having voting and dispositive power over the shares. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Epidarex on June 20, 2025.
On June 24, 2025, Sinclair also transferred 4,787 shares of Apellis Pharmaceuticals common stock to Epidarex Capital I LP for no consideration. Additionally, 3,837 shares were distributed from Epidarex to a Limited Partner and General Partner of Epidarex, also for no consideration.
In other recent news, Apellis Pharmaceuticals reported its second-quarter 2025 earnings, revealing a revenue of $178 million. This financial update highlights the company’s growth in revenue, despite a noted reduction in operating expenses. The earnings call also emphasized Apellis Pharmaceuticals’ strategic efforts to expand its product line and enhance its market presence. These developments reflect the company’s ongoing commitment to growth and innovation within its sector. Investors may find these updates significant as they evaluate Apellis Pharmaceuticals’ performance and future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.